Germany Market opportunities for biomedical companies
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Andreas Schmidt, CEO of Proteona, will be an invited speaker at the panel discussion on “Market Access: Germany: What, How, and Why Now?” during the Singapore Week of Innovation & Technology (SWITCH) 2020 conference. The panel discussion will take place at 17.00-18.00pm Singapore time, Friday, 11 December 2020.
Dr Schmidt will share his experience and insight on discovering business opportunities in Singapore, Germany, and beyond for biomedical companies. He will discuss the advantage of having an early presence in both Asia and Europe, and will provide advice for companies considering entering the Germany market.
Proteona is one such example. With operations in Singapore, Germany, and the US, Proteona is able to form close partnerships with pharmas, biotech companies, and clinicians around the globe and to stay at the forefront of science and innovation. Proteona has recently launched an international single cell multi-omics grant call, seeking ground-breaking ideas from around the world to make a difference in multiple myeloma treatment.
Other distinguished panellist in this session include Teodora Geogrieva, Programme Director, Scaler8, German Entrepreneurship Asia; Kristin Eckert, Senior Programme Manager, Scaler8, German Entrepreneurship Asia; and Dr Tan Teck Jack, Chief Medical Officer, TeleMedC.
Follow us on LinkedIn to stay updated!
The SWITCH conference is a leading technology innovation meeting in Asia. The week-long event provides a virtual platform for business matchmaking, start-up pitching, and talks by top industry speakers. SWITCH aims to bring together stake holders in innovation from the global community.
Join us at SWITCH 2020
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).